|
1
|
Nabhan C, Chaffee KG, Slager SL, Galanina
N, Achenbach SJ, Schwager SM, Kay NE and Shanafelt TD: Analysis of
racial variations in disease characteristics, treatment patterns,
and outcomes of patients with chronic lymphocytic leukemia. Am J
Hematol. Mar 25–2016.(Epub ahead of print). View Article : Google Scholar
|
|
2
|
Hallek M and Pflug N: Chronic lymphocytic
leukemia. Ann Oncol. 21(Suppl 7): vii154–vii164. 2010.PubMed/NCBI
|
|
3
|
Goldin LR, Pfeiffer RM, Li X and Hemminki
K: Familial risk of lymphoproliferative tumors in families of
patients with chronic lymphocytic leukemia: Results from the
Swedish Family-Cancer Database. Blood. 104:1850–1854. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feychting M, Forssén U and Floderus B:
Occupational and residential magnetic field exposure and leukemia
and central nervous system tumors. Epidemiology. 8:384–389. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohyashiki JH, Abe K, Ojima T, Wang P, Zhou
CF, Suzuki A, Ohyashiki K and Yamamoto K: Quantification of human
herpesvirus 6 in healthy volunteers and patients with
lymphoproliferative disorders by PCR-ELISA. Leuk Res. 23:625–630.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Laribi K, Tempescul A, Ghnaya H, Denizon
N, Besançon A, Anghel A, Farhi J, Truong C, Lemaire P, Poulain S,
Bolle D, Ianotto JC and de Materre A Baugier: The bendamustine plus
rituximab regimen is active against primary nodal marginal zone
B-cell lymphoma. Hematol Oncol. Jul 22–2016.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rioufol C and Salles G: Obinutuzumab for
chronic lymphocytic leukemia. Expert Rev Hematol. 1–11. 2014.
|
|
8
|
Cartron G, de Guibert S, Dilhuydy MS,
Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G,
Wenger M, et al: Obinutuzumab (GA101) in relapsed/refractory
chronic lymphocytic leukemia: Final data from the phase 1/2 GAUGUIN
study. Blood. 124:2196–2202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goede V, Fischer K, Busch R, Engelke A,
Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS,
Illmer T, et al: Obinutuzumab plus chlorambucil in patients with
CLL and coexisting conditions. N Engl J Med. 370:1101–1110. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brown J, O'Brien S, Kingsley C, Eradat H,
Pagel J, Lymp J, Hirata J and Kipps TJ: Obinutuzumab plus
fludarabine/cyclophosphamide or bendamustine in the initial therapy
of CLL patients: the phase 1b GALTON trial. Blood. 125:2779–2785.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robak T: Emerging monoclonal antibodies
and related agents for the treatment of chronic lymphocytic
leukemia. Future Oncol. 9:69–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Byrd JC, Pagel JM, Awan FT, Forero A,
Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK,
Leonard JP, et al: A phase 1 study evaluating the safety and
tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR
therapeutic protein in chronic lymphocytic leukemia. Blood.
123:1302–1308. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baum P, Cerveny C, Gordon B, Nilsson C,
Wiens J and Rafiq S: Evaluation of the effect of Tru-016, an
anti-CD37 directed SMIP in combination with other therapeutic drugs
in models of non-Hodgkin's lymphoma. J Clin Oncol. 27:Abs. 8571.
2009.
|
|
14
|
Robak T, Hellman A, Kloczko J, Loscertales
J, Lech-Maranda E, Pagel J, Mato AR, Byrd JC, Awan F, Hebart H, et
al: Phase 2 study of Otlertuzumab (TRU-016), an anti-CD37 ADAPTIR™
protein, in combination with Bendamustine vs Bendamustine alone in
patients with relapsed chronic lymphocytic leukemia (CLL) - updated
results. Blood. 124:56422014.
|
|
15
|
Maddocks K, Pagel J, O'Brien S, Byrd J,
Stromatt S and Awan F: Phase 1b study of Otlertuzumab (Tru-016), an
anti-CD37 ADAPTIR™ protein, in combination with rituximab in
patients with previously untreated chronic lymphocytic leukemia
(CLL). Blood (ASH Annual Meeting abstracts). 41652013.
|
|
16
|
Robak T: Emerging monoclonal antibodies
and related agents for the treatment of chronic lymphocytic
leukemia. Future Oncol. 9:69–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Durand J, Huchet V, Merieau E, et al:
Regulatory B Cells with a Partial Defect in CD40 Signaling and
Overexpressing Granzyme B Transfer Allograft Tolerance in Rodents.
J Immunol. 195:5035–5044. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dal Bo M, Tissino E, Benedetti D, Caldana
C, Bomben R, Del Poeta G, Gaidano G, Rossi FM, Zucchetto A and
Gattei V: Microenvironmental interactions in chronic lymphocytic
leukemia: The master role of CD49d. Semin Hematol. 51:168–176.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burger JA and Gribben JG: The
microenvironment in chronic lymphocytic leukemia (CLL) and other B
cell malignancies: Insight into disease biology and new targeted
therapies. Semin Cancer Biol. 24:71–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Friedberg JW, Sharman J, Sweetenham J, et
al: Inhibition of Syk with fostamatinib disodium has significant
clinical activity in non-Hodgkin lymphoma and chronic lymphocytic
leukemia. Blood. 115:2578–2585. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kadia T, Delioukina M, Kantarjian H,
Keating M, Wierda W, Burger J, Wieland S and Levitt D: A pilot
phase II study of the lyn kinase inhibitor bafetinib in patients
with relapsed or refractory B cell chronic lymphocytic leukemia.
Blood (ASH Annual Meeting abstracts). 118:28582011.
|
|
22
|
Herman SE, Gordon AL, Hertlein E,
Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy
JJ, et al: Bruton tyrosine kinase represents a promising
therapeutic target for treatment of chronic lymphocytic leukemia
and is effectively targeted by PCI-32765. Blood. 117:6287–6296.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Rooij MF, Kuil A, Geest CR, Eldering E,
Chang BY, Buggy JJ, Pals ST and Spaargaren M: The clinically active
BTK inhibitor PCI-32765 targets B-cell receptor- and
chemokine-controlled adhesion and migration in chronic lymphocytic
leukemia. Blood. 119:2590–2594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burger JA, Keating MJ, Wierda WG, Hartmann
E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli
A, Cardenas-Turanzas M, et al: Safety and activity of ibrutinib
plus rituximab for patients with high-risk chronic lymphocytic
leukaemia: A single-arm, phase 2 study. Lancet Oncol. 15:1090–1099.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Brien S, Furman RR, Coutre SE, Sharman
JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG,
et al: Ibrutinib as initial therapy for elderly patients with
chronic lymphocytic leukaemia or small lymphocytic lymphoma: An
open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 15:48–58.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Byrd JC, Brown JR, O'Brien S, Barrientos
JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et
al: RESONATE Investigators: Ibrutinib versus ofatumumab in
previously treated chronic lymphoid leukemia. N Engl J Med.
371:213–223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akinleye A, Chen Y, Mukhi N, Song Y and
Liu D: Ibrutinib and novel BTK inhibitors in clinical development.
J Hematol Oncol. 6:592013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lannutti BJ, Meadows SA, Herman SE,
Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM,
Deininger M, et al: CAL-101, a p110delta selective
phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell
malignancies, inhibits PI3K signaling and cellular viability.
Blood. 117:591–594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brown JR, Byrd JC, Coutre SE, Benson DM,
Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb
HK, et al: Idelalisib, an inhibitor of phosphatidylinositol
3-kinase p110δ, for relapsed/refractory chronic lymphocytic
leukemia. Blood. 123:3390–3397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fiorcari S, Brown WS, McIntyre BW, Estrov
Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG,
Keating MJ, et al: The PI3-kinase delta inhibitor idelalisib
(GS-1101) targets integrin-mediated adhesion of chronic lymphocytic
leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS
One. 8:e838302013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Patton DT, Garden OA, Pearce WP, Clough
LE, Monk CR, Leung E, Rowan WC, Sancho S, Walker LS, Vanhaesebroeck
B, et al: Cutting edge: The phosphoinositide 3-kinase p110 delta is
critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J
Immunol. 177:6598–6602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
O'Brien SM, Lamanna N, Kipps TJ, Flinn I,
Zelenetz AD, Burger JA, Holes L, Johnson DM, Gu J, Dansey RD, et
al: A phase II study of the selective phosphatidylinositol 3-kinase
delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with
rituximab (R) in treatment-naive patients (pts) ≥65 years with
chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma
(SLL). J Clin Oncol. 31:70052013.
|
|
33
|
Kipps TJ, Swinnen LJ, Wierda WG, Jones JA,
Coutre SE, Smith MR, Yang J, Cui Y, Busman T, Enschede S and
Humerickhouse R: Navitoclax (ABT-263) plus
fludarabine/cyclophosphamide/rituximab (FCR) or
bendamustine/rituximab (BR): A phase 1 study in patients with
relapsed/refractory chronic lymphocytic leukemia (CLL). Blood (ASH
Annual Meeting abstracts). 118:39042011.
|
|
34
|
Roberts AW, Ma S, Kipps TJ, Barrientos J,
Davids MS and Anderson MA: ABT-199 (GDC- 0199) combined with
rituximab (R) in patients (pts) with relapsed/refractory (R/R)
chronic lymphocytic leukemia (CLL): Interim results of a phase 1b
study. J Clin Oncol. 32:5s2014.
|
|
35
|
Johnson AJ, Yeh YY, Smith LL, Wagner AJ,
Hessler J, Gupta S, Flynn J, Jones J, Zhang X, Bannerji R, et al:
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965)
promotes apoptosis and abrogates microenvironmental cytokine
protection in chronic lymphocytic leukemia cells. Leukemia.
26:2554–2557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Flynn J, Andritsos LA, Jones JA, Johnson
AJ, Maddocks K, Wiley E, Small K, Im EK, Grever MR, Bannerji R, et
al: Dinaciclib (SCH 727965) is a novel Cyclin-Dependent Kinase
(CDK) inhibitor that exhibits activity in patients with relapsed or
refractory Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual
Meeting abstracts). 122:8712013.
|
|
37
|
Lin TS, Ruppert AS, Johnson AJ, Fischer B,
Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, et al:
Phase II study of flavopiridol in relapsed chronic lymphocytic
leukemia demonstrating high response rates in genetically high-risk
disease. J Clin Oncol. 27:6012–6018. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang JC, Kafeel MI, Avezbakiyev B, Chen C,
Sun Y, Rathnasabapathy C, Kalavar M, He Z, Burton J and Lichter S:
Histone deacetylase in chronic lymphocytic leukemia. Oncology.
81:325–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sampath D, Liu C, Vasan K, Sulda M,
Puduvalli VK, Wierda WG and Keating MJ: Histone deacetylases
mediate the silencing of miR-15a, miR-16, and miR-29b in chronic
lymphocytic leukemia. Blood. 119:1162–1172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bonfils C, Kalita A, Dubay M, Siu LL,
Carducci MA, Reid G, Martell RE, Besterman JM and Li Z: Evaluation
of the pharmacodynamic effects of MGCD0103 from preclinical models
to human using a novel HDAC enzyme assay. Clin Cancer Res.
14:3441–3449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
El-Khoury V, Pierson S, Szwarcbart E,
Brons NH, Roland O, Cherrier-De Wilde S, Plawny L, Van Dyck E and
Berchem G: Disruption of autophagy by the histone deacetylase
inhibitor MGCD0103 and its therapeutic implication in B-cell
chronic lymphocytic leukemia. Leukemia. 28:1636–1646. 2014.
View Article : Google Scholar : PubMed/NCBI
|
